CDEK
← All drugs Report issue

lysergic acid diethylamide

Small moleculeexperimental

Lysergic acid diethylamide, commonly known as LSD and by the slang names acid and lucy, is a semisynthetic hallucinogenic drug derived from ergot, known for its powerful psychological effects and serotonergic activity. It was historically used in psychiatry and 1960s counterculture; it is currently legally restricted but experiencing renewed scientific interest and increasing use. — Wikipedia

Clinical trial activity

46 trials · 26 clinical orgs · 0 marketing orgs

Phase 1
22
Phase 2
15
Phase 3
4
Phase 4
0

Earliest trial started Feb 1, 2008 (NCT00920387)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
Mol. weight
323.44 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 9,10-didehydro-6-methylergoline-8 beta-carboxamide
  • 9,10-didehydro-n,n-diethyl-6-methylergoline-8b-carboxamide
  • 9,10-didehydro-n,n-diethyl-6-methylergoline-8b-carboxamide
  • delysid
  • dextrolysergic acid diethylamide
  • dextrolysergic acid diethylamide
  • dextrolysergic acid diethylamide
  • diethylamid kyseliny lysergove
  • diethylamid kyseliny lysergove
  • d-lsd
  • d-lsd
  • d-lsd
  • d-lsd-25
  • d-lsd-25
  • d-lysergic acid amide
  • d-lysergic acid amide
  • d-lysergic acid dethylamide
  • d-lysergic acid dethylamide
  • d-lysergic acid diethylamide
  • d-lysergic acid diethylamide
  • d-lysergic acid diethylamide
  • d-lysergic acid n,n-diethylamide
  • d-lysergic acid n,n-diethylamide
  • lsd
  • lsd
  • lsd
  • lsd
  • lsd
  • (+)-lsd
  • (+)-lsd
  • lsd-25
  • lsd-25
  • lysergamid
  • lysergamid
  • lysergamide
  • lysergamide
  • lysergamide
  • lysergaure diethylamid
  • lysergaure diethylamid
  • lysergic acid amide
  • lysergic acid amide
  • lysergic acid amide
  • (+)-lysergic acid diethylamide
  • (+)-lysergic acid diethylamide
  • lysergic acid diethylamide
  • lysergic acid diethylamide
  • lysergic acid diethylamide
  • lysergic acid diethylamide
  • lysergic acid diethylamide
  • lysergic acid diethylamide
  • lysergic acid diethylamide-25
  • lysergic acid diethylamide-25
  • lysergide
  • lysergide
  • lysergide
  • lysergide
  • lysergide
  • lysergide
  • lysergidum
  • lysergidum
  • n,n-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
  • n,n-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
  • n,n-diethyl-d-lysergamide
  • n,n-diethyl-d-lysergamide
  • n,n-diethyllysergamide
  • n,n-diethyllysergamide
  • n,n-diethyl-(+)-lysergamide
  • n,n-diethyl-(+)-lysergamide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07309471N/AJan 31, 2026University of Basel
NCT07189299N/AOct 1, 2025University of Basel
NCT06735690Early Phase 1 (Phase 1)Aug 23, 2025City of Hope National Medical Center, National Cancer Institute (NCI)
NCT07061886Early Phase 1 (Phase 1)Jun 26, 2025National Institute on Drug Abuse (NIDA), University of Chicago
NCT07017478Early Phase 1 (Phase 1)Jun 9, 2025National Institute on Drug Abuse (NIDA), University of Chicago
NCT06941844Phase 3Apr 14, 2025Mind Medicine, Inc.
NCT06899334Phase 1Apr 1, 2025University of Basel
NCT06809595Phase 3Jan 29, 2025Mind Medicine, Inc.
NCT06741228Phase 3Dec 11, 2024Mind Medicine, Inc.
NCT06059391Phase 2Dec 25, 2023City of Hope National Medical Center, National Cancer Institute (NCI)
NCT05964647Phase 1Dec 1, 2023University of Basel
NCT05953038Early Phase 1 (Phase 1)Nov 8, 2023University of Copenhagen
NCT05976698N/ASep 30, 2023University of Basel
NCT05883540Phase 2Sep 30, 2023University of Basel, University of Zurich
NCT05711628Phase 3Aug 10, 2023ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
NCT05760066N/AAug 1, 2023Auburn University
NCT05477459Phase 2May 31, 2023Canisius-Wilhelmina Hospital, Donders Centre for Cognitive Neuroimaging, Leiden University, Radboud University, ZonMw: The Netherlands Organisation for Health Research and Development
NCT05807659Phase 2Mar 16, 2023Sichuan University
NCT05730166N/AFeb 15, 2023Universidad Rey Juan Carlos
NCT05730179N/AFeb 15, 2023Universidad Rey Juan Carlos
Showing 20 of 46 trials
Page 1 / 3

Organizations

Research & Development (26)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of BaselAcademic/Hospital161632017
University of BernAcademic/Hospital5422013
University of ChicagoAcademic/Hospital4412018
Mind Medicine, Inc.For profit3312024
National Cancer Institute (NCI)Government3132023
Universidad Rey Juan CarlosAcademic/Hospital3312023
City of Hope National Medical CenterAcademic/Hospital2222023
Eleusis TherapeuticsFor profit2212015
National Institute on Drug Abuse (NIDA)Government2012025
University of ZurichAcademic/Hospital2122015
Auburn UniversityAcademic/Hospital1112023
Canisius-Wilhelmina HospitalAcademic/Hospital1012023
Donders Centre for Cognitive NeuroimagingAcademic/Hospital1012023
ECOG-ACRIN Cancer Research GroupAcademic/Hospital1012023
Jiao Tong UniversityAcademic/Hospital1112023
Johns Hopkins UniversityAcademic/Hospital1112014
Leiden UniversityAcademic/Hospital1012023
Maastricht UniversityAcademic/Hospital1112023
Multidisciplinary Association for Psychedelic StudiesAcademic/Hospital1112008
Radboud UniversityAcademic/Hospital1112023
26 organizations
Page 1 / 2